Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  entinostat
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNDX-275-0601, NCI-2015-01180, NCT02437136
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNDX-275-0602, NCI-2016-01257, NCT02708680
Azacitidine, Entinostat, and Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1353, NCI-2013-02334, NA_00084192, NA_00084192/CIR00003289, NCT01928576
Entinostat, Nivolumab, and Ipilimumab in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9844, NCI-2015-00741, J15221, L9844, SKCCC J15221, NCT02453620
Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1513, NCI-2016-00708, NCT02780804
Entinostat and Pembrolizumab in Treating Patients with Myelodysplastic Syndrome after DNMTi Therapy Failure
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10009, NCI-2016-01501, NCT02936752
Start Over